Fabrication of Gold Nanoparticles for Targeted Therapy in Pancreatic Cancer

Overview

Journal Adv Drug Deliv Rev

Specialty Pharmacology

Date 2009 Nov 17

PMID 19914317

Citations 98

Authors

Chitta Ranjan Patra

Resham Bhattacharya

Debabrata Mukhopadhyay

Priyabrata Mukherjee

Affiliations

Soon will be listed here.

Abstract

The targeted delivery of a drug should result in enhanced therapeutic efficacy with low to minimal side effects. This is a widely accepted concept, but limited in application due to lack of available technologies and process of validation. Biomedical nanotechnology can play an important role in this respect. Biomedical nanotechnology is a burgeoning field with myriads of opportunities and possibilities for advancing medical science and disease treatment. Cancer nanotechnology (1-100 nm size range) is expected to change the very foundations of cancer treatment, diagnosis and detection. Nanomaterials, especially gold nanoparticles (AuNPs) have unique physico-chemical properties, such as ultra small size, large surface area to mass ratio, and high surface reactivity, presence of surface plasmon resonance (SPR) bands, biocompatibility and ease of surface functionalization. In this review, we will discuss how the unique physico-chemical properties of gold nanoparticles may be utilized for targeted drug delivery in pancreatic cancer leading to increased efficacy of traditional chemotherapeutics.

Citing Articles

Gold Nanoparticles: Multifunctional Properties, Synthesis, and Future Prospects.

Duman H, Akdasci E, Eker F, Bechelany M, Karav S Nanomaterials (Basel). 2024; 14(22).

PMID: 39591046 PMC: 11597081. DOI: 10.3390/nano14221805.

The Mechanism and Latest Research Progress of Blood-Brain Barrier Breakthrough.

Wang F, Qi L, Zhang Z, Duan H, Wang Y, Zhang K Biomedicines. 2024; 12(10).

PMID: 39457617 PMC: 11504064. DOI: 10.3390/biomedicines12102302.

Amelioration of gold nanoparticles mediated through oil extracts induces reactive oxygen species and mitochondrial instability against MCF-7 breast carcinoma.

Mohanta Y, Biswas K, Mishra A, Patra B, Mishra B, Panda J RSC Adv. 2024; 14(38):27816-27830.

PMID: 39224640 PMC: 11367626. DOI: 10.1039/d4ra04807e.

PEGylated Micro/Nanoparticles Based on Biodegradable Poly(Ester Amides): Preparation and Study of the Core-Shell Structure by Synchrotron Radiation-Based FTIR Microspectroscopy and Electron Microscopy.

Makharadze D, Kantaria T, Yousef I, Del Valle L, Katsarava R, Puiggali J Int J Mol Sci. 2024; 25(13).

PMID: 39000109 PMC: 11241343. DOI: 10.3390/ijms25136999.

Prospect of Gold Nanoparticles in Pancreatic Cancer.

Yin T, Han J, Cui Y, Shang D, Xiang H Pharmaceutics. 2024; 16(6).

PMID: 38931925 PMC: 11207630. DOI: 10.3390/pharmaceutics16060806.

References

Harsha H, Jimeno A, Molina H, Mihalas A, Goggins M, Hruban R . Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. J Proteome Res. 2008; 7(11):4651-8. DOI: 10.1021/pr800139r. View

Haemmerich D, Laeseke P . Thermal tumour ablation: devices, clinical applications and future directions. Int J Hyperthermia. 2005; 21(8):755-60. DOI: 10.1080/02656730500226423. View

Li C, Cai W, Li Y, Hu J, Liu P . Ultrasonically induced Au nanoprisms and their size manipulation based on aging. J Phys Chem B. 2006; 110(4):1546-52. DOI: 10.1021/jp055522l. View

Zapata M, Cohen C, Siddiqui M . Immunohistochemical expression of SMAD4, CK19, and CA19-9 in fine needle aspiration samples of pancreatic adenocarcinoma: Utility and potential role. Cytojournal. 2007; 4:13. PMC: 1936432. DOI: 10.1186/1742-6413-4-13. View

Matlashewski G, Lamb P, Pim D, Peacock J, Crawford L, Benchimol S . Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO J. 1984; 3(13):3257-62. PMC: 557846. DOI: 10.1002/j.1460-2075.1984.tb02287.x. View

Kuo T, Kubota T, Watanabe M, Furukawa T, Kase S, Tanino H . Site-specific chemosensitivity of human small-cell lung carcinoma growing orthotopically compared to subcutaneously in SCID mice: the importance of orthotopic models to obtain relevant drug evaluation data. Anticancer Res. 1993; 13(3):627-30. View

Uegaki K, Nio Y, Inoue Y, Minari Y, Sato Y, Song M . Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res. 1998; 17(5B):3841-7. View

Kinsella A, Smith D, Pickard M . Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage. Br J Cancer. 1997; 75(7):935-45. PMC: 2222738. DOI: 10.1038/bjc.1997.164. View

Nakamoto M, Yamamoto M, Fukusumi M . Thermolysis of gold(I) thiolate complexes producing novel gold nanoparticles passivated by alkyl groups. Chem Commun (Camb). 2002; (15):1622-3. DOI: 10.1039/b203736j. View

10.

Oida Y, Gopalan B, Miyahara R, Branch C, Chiao P, Chada S . Inhibition of nuclear factor-kappaB augments antitumor activity of adenovirus-mediated melanoma differentiation-associated gene-7 against lung cancer cells via mitogen-activated protein kinase kinase kinase 1 activation. Mol Cancer Ther. 2007; 6(4):1440-9. DOI: 10.1158/1535-7163.MCT-06-0374. View

11.

Hoffmann R, Jakobs T, Trumm C, Weber C, Helmberger T, Reiser M . Radiofrequency ablation in combination with osteoplasty in the treatment of painful metastatic bone disease. J Vasc Interv Radiol. 2008; 19(3):419-25. DOI: 10.1016/j.jvir.2007.09.016. View

12.

Burris H, Storniolo A . Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer. 1997; 33 Suppl 1:S18-22. DOI: 10.1016/s0959-8049(96)00324-3. View

13.

Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V . Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology. 2006; 70(4):255-64. DOI: 10.1159/000094888. View

14.

Erlichman C, Hidalgo M, Boni J, Martins P, Quinn S, Zacharchuk C . Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol. 2006; 24(15):2252-60. DOI: 10.1200/JCO.2005.01.8960. View

15.

Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T . CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 2008; 9(2):132-8. DOI: 10.1016/S1470-2045(08)70001-9. View

16.

Kovar M, Kovar L, Subr V, Etrych T, Ulbrich K, Mrkvan T . HPMA copolymers containing doxorubicin bound by a proteolytically or hydrolytically cleavable bond: comparison of biological properties in vitro. J Control Release. 2004; 99(2):301-14. DOI: 10.1016/j.jconrel.2004.07.015. View

17.

Ajani J, Abbruzzese J, Goudeau P, Faintuch J, Yeomans A, Boman B . Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. J Clin Oncol. 1988; 6(11):1703-7. DOI: 10.1200/JCO.1988.6.11.1703. View

18.

Kayed H, Kleeff J, Keleg S, Guo J, Ketterer K, Berberat P . Indian hedgehog signaling pathway: expression and regulation in pancreatic cancer. Int J Cancer. 2004; 110(5):668-76. DOI: 10.1002/ijc.20194. View

19.

Hoekstra R, Dumez H, Eskens F, van der Gaast A, Planting A, de Heus G . Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin Cancer Res. 2005; 11(19 Pt 1):6908-15. DOI: 10.1158/1078-0432.CCR-05-0720. View

20.

Loo C, Lowery A, Halas N, West J, Drezek R . Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett. 2005; 5(4):709-11. DOI: 10.1021/nl050127s. View